ATHE - Rega marang dodolan Alterity Therapeutics
The completion of Phase II trials for its Parkinson's disease drug will be the key driver for Alterity Therapeutics (ATHE), with the current metric value standing at 2.20. P/S fluctuations visualize market expectations amid a lack of profitability. Alterity Therapeutics (ATHE) is implementing bioethical principles and minimizing chemical waste. Patient safety is guaranteed by strict temperature control during the transportation of medications to clinics.
Rincian analitis perusahaan Alterity Therapeutics (ATHE)
- kuotasi lan prakiraan analis:
- statistik kapitalisasi pasar:
- data nilai buku modal saham:
- rincian struktur utang lan likuiditas bisnis:
Rasio Kabeh Utang marang Dana Pribadi Alterity Therapeutics|ATHE - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal alteritytherapeutics.com|ATHE - Utang perusahaan|Rasio utang marang aset resik Alterity Therapeutics Ltd|ATHE - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Alterity Therapeutics|Rasio likuiditas kritis alteritytherapeutics.com
- informasi bathi lan kelipatan valuasi:
ATHE - Bathi resik|Bathi resik sing dikarepake Alterity Therapeutics|ATHE - Koefisien rega marang bathi|Pangali Forward P/E alteritytherapeutics.com|ATHE - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Alterity Therapeutics Ltd|ATHE - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Alterity Therapeutics|ATHE - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan alteritytherapeutics.com|ATHE - Wutah bathi saben saham ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Alterity Therapeutics
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis fundamental perusahaan:Alterity Therapeutics Ltd., ATHE
To diversify my portfolio with high-quality assets, I utilize the valuation of market capitalization relative to annual revenue. This metric measures the cost of one dollar of sales, determining the extent of the premium paid for the business. For Alterity Therapeutics (ATHE), with its exclusive patents for brain degeneration drugs, this calculation reflects market expectations for future R&D success. The current price-to-sales ratio of 2.20 allows for a timely adjustment of the investment strategy.
Perusahaan pesaing
Kapitalisasi marang volume dodolan BIIB|Neurocrine Biosciences, Inc. - Kapitalisasi marang pendapatan|Regencell Bioscience Ltd (RGC) - Rega marang dodolan|AXSM: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Corp)|XENE (Xenon Pharmaceuticals) - Kapitalisasi marang pendapatan|VKTX: Kapitalisasi marang volume dodolan|SUPN (Supernus) - Multiplikator P/S|CPRX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DNLI|HRMY - Rega marang dodolan|Rasio rega marang pendapatan Biohaven Ltd. BHVN|Rasio kapitalisasi pasar marang pendapatan AMLX|Trevi Therapeutics, Inc. - Multiplikator P/S|PRAX - Multiplikator P/S|Anavex Corp (AVXL) - Rasio rega marang pendapatan|Rasio rega marang dodolan CBLL (CeriBell EEG)|PRTA (Prothena Biosciences) - Multiplikator P/S|Rega marang dodolan Alector Therapeutics ALEC|Kapitalisasi marang pendapatan ANNX (Annexon)|Multiplikator P/S omeros.com (OMER)|Neurogene Corp - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan ACIU (AC Immune Inc)|Voyager Therapeutics - Multiplikator P/S|Koefisien rega marang pendapatan neumoratx.com NMRA|SCLX: Multiplikator P/S|Kapitalisasi marang pendapatan Tevogen Bio Holdings Inc.|Rasio rega marang pendapatan Alpha Cognition Inc|Cognition Therapeutics Inc. (CGTX) - Koefisien rega marang pendapatan|Multiplikator P/S IKT|Multiplikator P/S cassavasciences.com (SAVA)|Assertio - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan COYA (Coya Therapeutics Inc)|VistaGen Therapeutics Inc - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan OVID (Ovid Therapeutics Inc.)|ABOS: Multiplikator P/S|Rega marang dodolan cervomed.com (CRVO)|Rasio rega marang pendapatan Clene Inc|Rasio kapitalisasi marang pendapatan PEPG (PepGen Corp)|Multiplikator P/S JUNS|RLMD - Rega marang dodolan|Annovis Bio, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S Grace Therapeutics Inc GRCE|AIFF - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan KLTO (Klotho Neurosciences Inc)|neurosense-tx.com (NRSN) - Rasio rega marang pendapatan|Rega marang dodolan Reviva Pharmaceuticals, Inc. (RVPH)|MTVA (MetaVia Inc.) - Multiplikator P/S|Multiplikator P/S neuraxis.com|Rasio rega marang pendapatan Helius Medical (HSDT)|Rasio rega marang pendapatan PASG (passagebio.com)|Neuphoria Therapeutics - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan NERV (Minerva)|Athira Pharma, Inc. - Multiplikator P/S|Rega marang dodolan addextherapeutics.com|alzamend.com (ALZN) - Rasio rega marang pendapatan|Cyclerion Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan|PTIX (Protagenic Therapeutics Inc.) - Multiplikator P/S|Pasithea (KTTA) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan CRGT (Cortigent, Inc.)|Kapitalisasi marang volume dodolan ATXI|BrainStorm Cell Therapeutics - Kapitalisasi marang pendapatan|Cara Therapeutics Inc. (CARA) - Rega marang dodolan|CHRO: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ELYM (Eliem Therapeutics)|ITCI (intracellulartherapies.com) - Kapitalisasi marang pendapatan|LBPH: Kapitalisasi marang volume dodolan|MRNS (Marinus Pharmaceuticals, Inc.) - Multiplikator P/S|NKGN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NRBO|SAGE - Rega marang dodolan|Rasio rega marang pendapatan Synaptogenix, Inc. SNPX|Rasio kapitalisasi pasar marang pendapatan TRVN|Vigil Neuro - Multiplikator P/S|WENA - Multiplikator P/S|Cerevel (CERE) - Rasio rega marang pendapatan
